Micutan (Terbinafine)

Terbinafine, the active ingredient in Micutan, is a allylamine antifungal presented as an oral tablet for oral use. It treats fungal infections of the skin and nails, including onychomycosis, tinea pedis and tinea corporis, in adult patients. GNH USA supplies Micutan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micutan (terbinafine) is indicated for fungal infections affecting the skin and nails. - Onychomycosis: eradicates the causative dermatophytes, leading to regrowth of healthy nail tissue. - Tinea pedis: relieves foot fungal infection, reducing scaling and itching. - Tinea corporis: clears body ringworm lesions, restoring normal skin appearance.

Terbinafine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort or diarrhea. - Skin reactions: rash, pruritus or mild erythema. - Taste disturbances: dysgeusia or loss of taste. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: hepatitis, jaundice or severe liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia or agranulocytosis. - Peripheral neuropathy: numbness or tingling in extremities. - Severe allergic reactions: anaphylaxis or angioedema.

Before prescribing Micutan, clinicians should consider several safety aspects. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Drug interactions: review concomitant medications that affect CYP450 enzymes. - Renal impairment: adjust therapy if significant renal dysfunction is present. - Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. - Age considerations: use caution in elderly patients due to potential comorbidities. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Terbinafine can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase terbinafine levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Cimetidine: can raise terbinafine plasma concentration.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect changes. - Antidepressants metabolized by CYP2C9/2C19: observe for altered plasma levels. - HIV protease inhibitors: assess for increased risk of hepatotoxicity.